Novartis, MMV extend malaria drug pact | Chemical & Engineering News
Volume 94 Issue 26 | p. 13 | Concentrates
Issue Date: June 27, 2016

Novartis, MMV extend malaria drug pact

Department: Business
Keywords: drug development, pharmaceuticals, biotech, malaria

As part of a broadened pact with the nonprofit Medicines for Malaria Venture, Novartis will lead the development of the antimalarial KAF156, currently in Phase IIb studies. KAF156 belongs to a new class of compounds called imidazolepiperazines, which are able to take down the parasite that causes malaria in both the liver and blood stage of its reproductive cycle. The compound has the potential to address multi-drug-resistant strains of the infection.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment